Reaction

Gastric Infection reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,776 reports · 102 co-occurring drugs

As of the last recalculation, Gastric Infection appears in 3,776 FAERS reports alongside 102 co-occurring drug terms. The strongest observed disproportionality signal is ADO-TRASTUZUMAB EMTANSINE (PRR 13.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ado-Trastuzumab Emtansine	20	13.1	13.2
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	68	12.3	12.3
Human Immunoglobulin G	42	11.3	11.4
Diphenhydramine Hydrochloride Capsule, Liquid Filled	32	8.3	8.3
Dimenhydrinate	16	8.3	8.3
Dronabinol	12	8.2	8.3
Diphenhydramine	80	7.1	7.1
Adrenalinum	50	6.7	6.7
Niraparib	25	6.2	6.2
Cyclobenzaprine Hydrochloride	10	6.1	6.2
Dicyclomine Hydrochloride	15	5.8	5.8
Rabeprazole	23	5.8	5.8
Upadacitinib	82	5.6	5.7
Risankizumab-Rzaa	81	5.6	5.6
Epinephrine	65	5.6	5.6
Ocrelizumab	61	5.5	5.5
Hyoscyamine Sulfate	9	5.4	5.4
Agalsidase Beta	9	5.4	5.4
Epoprostenol	12	5.1	5.1
Promethazine Hydrochloride	17	5.1	5.1
Teduglutide	12	4.9	4.9
Dexamethasone Sodium Phosphate	9	4.9	4.9
Cetirizine Hcl	8	4.8	4.8
Tocilizumab	97	4.8	4.8
Paroxetine Hydrochloride Hemihydrate	27	4.5	4.5
Emicizumab	10	4.5	4.5
Paroxetine	27	4.4	4.4
Sucralfate	19	4.4	4.4
Terazosin Hydrochloride	7	4.3	4.3
Sucralfate Oral	11	4.3	4.3
Sucralfate Oral Suspension	11	4.3	4.3
Riociguat	25	4.2	4.3
Lidocaine	44	4.2	4.2
Alendronate Sodium Tablet	14	4.2	4.2
Quetiapine Fumarate	22	4.1	4.1
Benzonatate	12	4.0	4.0
Golimumab	61	4.0	4.0
Oxybutynin Chloride	6	3.8	3.8
Azelastine	12	3.7	3.7
Haloperidol	16	3.6	3.6
Patiromer	9	3.6	3.6
Haloperidol Lactate	16	3.6	3.6
Nintedanib	20	3.5	3.5
Ivacaftor	5	3.5	3.5
Irinotecan Hydrochloride	8	3.4	3.4
Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose	5	3.4	3.4
Oxazepam	13	3.3	3.3
Ustekinumab	61	3.3	3.3
Adalimumab	386	3.2	3.2
Macitentan	40	3.2	3.2
Treprostinil	68	3.0	3.0
Mepolizumab	27	3.0	3.0
Pirfenidone	22	3.0	3.0
Interferon Beta-1B	10	2.9	2.9
Abatacept	69	2.8	2.8
Pancrelipase	19	2.7	2.7
Ambrisentan	60	2.7	2.7
Trastuzumab	33	2.7	2.7
Nilotinib	14	2.6	2.6
Belimumab	15	2.6	2.6
Lumacaftor And Ivacaftor	4	2.6	2.6
Tadalafil	46	2.6	2.6
Dornase Alfa	9	2.5	2.5
Rucaparib	4	2.5	2.5
Ixazomib	13	2.5	2.5
Nevirapine	4	2.4	2.4
Tofacitinib	80	2.4	2.4
Orlistat	11	2.3	2.3
Paricalcitol	6	2.3	2.3
Naltrexone	13	2.3	2.3
Ofatumumab	14	2.3	2.3
Avapritinib	5	2.3	2.3
Certolizumab Pegol	48	2.3	2.3
Asfotase Alfa	4	2.2	2.2
Rifaximin	8	2.1	2.1
Bimekizumab	8	2.1	2.1
Venetoclax	22	2.0	2.0
Bosentan	18	2.0	2.0
Sevelamer Carbonate	4	1.9	1.9
Secukinumab	55	1.9	1.9
Dextrose Monohydrate, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	3	1.9	1.9
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	14	1.9	1.9
Teriflunomide	15	1.8	1.8
Etanercept	193	1.8	1.8
Palivizumab	5	1.8	1.8
Rimegepant Sulfate	4	1.7	1.7
Pomalidomide	32	1.7	1.7
Ledipasvir And Sofosbuvir	6	1.7	1.7
Axitinib	6	1.7	1.7
Dimethyl Fumarate	37	1.7	1.7
Fam-Trastuzumab Deruxtecan-Nxki	3	1.6	1.6
Lenalidomide	114	1.5	1.5
Ixekizumab	10	1.5	1.5
Palbociclib	25	1.4	1.4
Olaparib	5	1.3	1.3
Valbenazine	6	1.3	1.3
Velpatasvir And Sofosbuvir	3	1.3	1.3
Natalizumab	39	1.2	1.2
Guselkumab	7	1.1	1.1
Apremilast	26	1.0	1.0
Evolocumab	19	0.6	0.6
Pimavanserin Tartrate	5	0.5	0.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.